Preclinical Properties of Budesonide: Translation to the Clinical Setting

Clinical Therapeutics

Volumn 25, Issue SUPPL. C, 2003, Pages

  Pearlman, David S ^a  

^a Respiratory Institute   (United States)

Author keywords

Budesonide; Early intervention; Efficacy; Inhaled corticosteroid; Tolerability

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PULMICORT RESPULE; SALBUTAMOL; TERBUTALINE; TRIAMCINOLONE ACETONIDE;

ASTHMA; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DYSPHONIA; DYSPNEA; EARLY DIAGNOSIS; GROWTH RETARDATION; HOARSENESS; HUMAN; INFLAMMATION; MEDICAL NEBULIZER; METERED DOSE INHALER; POWDER INHALER; PREDICTION; REVIEW; SYMPTOM; WHEEZING;

EID: 0242406642     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80307-7     Document Type: Article

References (96)

1. Bel EH, Timmers MC, Zwinderman AH, et al. The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. Am Rev Respir Dis. 1991;143:109-113.
2. Smith MJ, Hodson ME. High-dose beclomethasone inhaler in the treatment of asthma. Lancet. 1983;1:265-269.
3. Laursen LC, Taudorft E, Weeke B. High-dose inhaled budesonide in treatment of severe steroid-dependent asthma. Eur J Respir Dis. 1986;68:19-28.
4. Utiger RD. Differences between inhaled and oral glucocorticoid therapy. N Engl J Med. 1993;329:1731-1733.
5. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol. 1992;90:32-42.
6. Jeffery P. Pathology of asthma. Br Med Bull. 1992;48:23-39.
7. Dompeling E, van Schayck CP, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med. 1993;118:770-778.
8. Bousquet J. Relating inflammatory changes in asthma to clinical status. Respir Med. 2000;94(Suppl F):S32-S33.
9. Vignola AM, Mirabella F, Costanzo G, et al. Airway remodelling in asthma. Chest. 2003;123(Suppl 3):S417-S422.
10. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 1998;157(Suppl):S1-S53.
11. British guidelines on asthma management: 1995 review and position statement. Thorax. 1997;52(Suppl 1):S1-S21.
12. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Bethesda, Md: National Institutes of Health, National Heart, Lung and Blood Institute; 1998. Publication 96-3659B.
13. Gerdtham UG, Hertzman P, Jönsson B, Boman G. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991. Med Care. 1996;34:1188-1198.
14. Blais L, Suissa S, Boivin JF, Ernst P. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax. 1998;53:1025-1029.
15. Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma - United States, 1980-1999. MMWR Surveil Summ. 2002;51:1-13.
16. Brogger J, Bakke P, Eide GE, et al. Long-term changes in adult asthma prevalence. Eur Respir J. 2003;21:468-472.
17. Banov C, Howland WC III, Lumry WR, et al. Budesonide Turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma. Allergy Asthma Proc. 2003;24:129-136.
18. Kondo T, Tanigaki T, Ono Y, et al. Impact of fluticasone Diskhaler on health-related quality of life in asthmatic patients. Tokai J Exp Clin Med. 2002;27:79-84.
19. Thorsson L, Thunnisen FB, Korn S, et al. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo. Am J Respir Crit Care Med. 1998;157(Suppl 3): A404. Abstract.
20. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther. 2003;25(Suppl C):C28-C41.
21. Miller-Larsson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998;26:623-630.
22. Miller-Larsson A, Ivarsson R, Mattsson H, et al. High capacity of airway/lung tissue for budesonide esterification as compared to peripheral striated muscles. Eur Respir J. 1999;14(Suppl 30):S195. Abstract.
23. Miller-Larsson A, Jansson P, Runström A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med. 2000;162:1455-1461.
24. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler™ is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994:7:1839-1844.
25. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol. 2000;40:1227-1236.
26. Thorsson L, Dahlström K, Edsbäcker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1997;43: 155-161.
27. O'Connell EJ. Review of the unique properties of budesonide. Clin Ther. 2003;25(Suppl C):C42-C60.
28. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S440-S446.
29. Thorsson L, Kallen A, Wirén JE, Paulson J. Pharmacokinetics of inhaled fluticasone propionate. Am J Respir Crit Care Med. 1996;153:A801. Abstract.
30. Kemp JP. Expected characteristics of an ideal, all-purpose inhaled corticosteroid for the treatment of asthma. Clin Ther. 2003;25(Suppl C):C15-C27.
31. Skoner DP. Therapeutic margin of budesonide in patients with mild to severe asthma. Clin Ther. 2003;25(Suppl C):C61-C74.
32. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J. 1996;9:1427-1432.
33. Grahnén A, Jansson B, Brundin RM, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur J Clin Pharmacol. 1997;52:261-267.
34. Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52:529-538.
35. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, Md: National Institutes of Health; 2002. Publication 02-3659.
36. Lofdahl CG, Mellstrand T, Svedmyr N. Glucocorticoids and asthma. Studies of resistance and systemic effects of glucocorticoids. Eur J Respir Dis Suppl. 1984;136:69-79.
37. Jennings B, Larsson B, Andersson K, Johansson S. The assessment of systemic effects of inhaled glucocorticosteroids: A comparison of budesonide and beclomethasone dipropionate in healthy volunteers. In: Jennings B, ed. Assessment of Systemic Effects of Inhaled Glucocorticosteroids [thesis]. Lund, Sweden: University of Lund; 1990:1-14.
38. Brutsche MH, Brutsche IC, Munavvr M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study. Lancet. 2000;356:556-561.
39. Harrison TW, Wisniewski A, Honour J, Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax. 2001;56:186-191.
40. O'Byrne P, Cuddy L, Taylor DW, et al. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J. 1996;3:169-175.
41. Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994;331:700-705.
42. Selroos O, Pietinalho A, Löfroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest. 1995;108:1228-1234.
43. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, Md: National Institutes of Health, National Heart, Lung and Blood Institute; 1995. Publication 95-3659.
44. Haahtela T, Järvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325:388-392.
45. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88:373-381.
46. Szefler SJ. The changing faces of asthma. J Allergy Clin Immunol. 2000;106(Suppl 3): S139-S143.
47. Pauwels RA, Busse WW, O'Byrne PM, et al. The inhaled Steroid Treatment As Regular Therapy in early asthma (START) study: Rationale and design. Control Clin Trials. 2001;22:405-419.
48. Pauwels R, Pedersen S, Busse W, et al. Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet. 2003;361:1071-1076.
49. Chapman KR. The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults. Clin Ther. 2003;25(Suppl C): C2-C14.
50. Campbell LM, Watson DG, Venables TL, et al. Once daily budesonide Turbohaler compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res. 1991;2:111-122.
51. Jones AH, Langdon CG, Lee PS, et al. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med. 1994;88:293-299.
52. Campbell LM, Gunn SD, Sweeney D, et al. Once daily budesonide: Effective control of moderately severe asthma with 800 μg once daily inhaled Turbohaler when compared with 400 μg twice daily. Eur J Clin Res. 1995;7:1-14.
53. McFadden ER, Casale TB, Edwards TB, et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J Allergy Clin Immunol. 1999;104:46-52.
54. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma [published erratum appears in J Allergy Clin Immunol. 1998;102:511]. J Allergy Clin Immunol. 1998;101:457-463.
55. McFadden ER. Budesonide Turbuhaler® once daily administration for patients with mild to moderate chronic asthma. Am J Respir Crit Care Med. 1997;155:A352. Abstract.
56. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: A review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs. 2000;60: 1141-1178.
57. Mellon M, for the Budesonide Inhalation Suspension Study Group. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol. 1999;104:191-199.
58. Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol. 1999;104:200-209.
59. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr. 1998;132:976-982.
60. Szefler SJ, Nelson HS. Alternative agents for anti-inflammatory treatment of asthma. J Allergy Clin Immunol. 1998;102:S23-S35.
61. Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999;103:414-421.
62. Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol. 1999;83:231-239.
63. Higenbottam TW, Clark RA, Luksza AR, et al. The role of nebulised budesonide in permitting a reduction in the dose of oral steroid in persistent severe asthma. Eur J Clin Res. 1994;5:1-10.
64. O'Connor B, Basran G, O'Connell F, O'Shaughnessy K. Oral steroid-sparing effect of nebulized budesonide in chronic severe asthma. Am J Respir Crit Care Med. 1996;153: A341. Abstract.
65. Connolly KC, Peake MD, Halpin DMG, et al. Challenging current asthma treatment guidelines. Improved control of asthma symptoms with nebulised budesonide in patients with severe asthma receiving continuous oral steroids. Dis Manage Health Outcomes. 2000;7:217-225.
66. Borgström L, Derom E, Ståhl E, et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med. 1996;153: 1636-1640.
67. Borgstrom L. Local versus total systemic bioavailability as a means to compare different inhaled formulations of the same substance. J Aerosol Med. 1998;11:55-63.
68. Agertoft L, Pedersen S, Nikander K. Drug delivery from the Turbuhaler and Nebuhaler pressurized metered dose inhaler to various age groups of children with asthma. J Aerosol Med. 1999;12:161-169.
69. Brown PH, Ning AC, Greening AP, et al. Peak inspiratory flow through Turbuhaler in acute asthma. Eur Respir J. 1995;8:1940-1941.
70. Ståhl E, Ribeiro LB, Sandahl G. Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler® in children with mild to moderate asthma. Pediatr Pulmonol. 1996;22:106-110.
71. Jonasson G, Carlsen KH, Jonasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy. 2000;55:740-748.
72. Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol. 1997;99:773-780.
73. Boulet LP, Becker A, Ernst P, et al, for the Canadian Asthma Consensus Group. Canadian Asthma Consensus Report, 1999. CMAJ. 1999;161(Suppl 11):S1-S61.
74. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health, National Heart, Lung and Blood Institute; 1997. Publication 97-4051.
75. O'Byrne PM, Barnes PJ, Rodriguez-Roison R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-1397.
76. Mann M, Eliasson O, Patel K, ZuWallack RL. A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide. Chest. 1992;101:496-499.
77. Venables TL, Addlestone MB, Smithers AJ, et al. A comparison of the efficacy and patient acceptability of once daily budesonide via Turbohaler and twice daily fluticasone propionate via disc-inhaler at an equal daily dose of 400 μg in adult asthmatics. Br J Clin Res. 1996;7:15-32.
78. McFadden ER, Casale TB, Edwards TB, et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J Allergy Clin Immunol. 1999; 104:46-52.
79. Banov CH, Howland WCI, Lumry WR. Once-daily budesonide via Turbuhaler improves symptoms in adults with persistent asthma. Ann Allergy Asthma Immunol. 2001;86:627-632.
80. Herjavecz I, Blomqvist P, Serrano A. Efficacy of once-and twice-daily administration of budesonide via Turbuhaler as initial therapy in patients with mild persistent asthma. Respir Med. 1999;93:230-235.
81. Campbell LM, Bodalia B, Gogbashian CA, et al, for the PETITE Research Group. Once-daily budesonide: 400 micrograms once daily is as effective as 200 micrograms twice daily in controlling childhood asthma. Int J Clin Pract. 1998;52:213-219.
82. Jonasson G, Carlsen KH, Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J. 1998;12:1099-1104.
83. Möller C, Strömberg L, Oldaeus G, et al. Efficacy of once-daily versus twice-daily administration of budesonide by Turbuhaler® in children with stable asthma. Pediatr Pulmonol. 1999;28:337-343.
84. Shapiro GG, Mendelson LM, Pearlman DS. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids. Ann Allergy Asthma Immunol. 2001;86:633-640.
85. Nelson HS, Bernstein L, Fink J, et al, for the Pulmicort Turbuhaler Study Group. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: A double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Chest. 1998;113:1264-1271.
86. Engel T, Heinig JH, Malling HJ, et al. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy. 1989;44: 220-225.
87. Selroos O, Backman R, Forsén KO, et al. Local side-effects during 4-year treatment with inhaled corticosteroids - a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy. 1994;49:888-890.
88. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(Suppl 39):1-34.
89. Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax. 2001;56:272-278.
90. Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care Med. 1998;157:178-183.
91. Heuck C, Wolthers OD, Kollerup G, et al. Adverse effects of inhaled budesonide (800 micrograms) on growth and collagen turnover in children with asthma: A double-blind comparison of once-daily versus twice-daily administration. J Pediatr. 1998;133: 608-612.
92. Allen DB, Bronsky EA, LaForce CF, et al, for the Fluticasone Propionate Asthma Study Group. Growth in asthmatic children treated with fluticasone propionate. J Pediatr. 1998;132:472-477.
93. Rao R, Gregson RK, Jones AC, et al. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: A comparison of fluticasone with beclomethasone. Eur Respir J. 1999;13:87-94.
94. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: A meta-analysis. Pediatrics [serial online]. July 2000;106: E8.
95. Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med. 2001;164:521-535.
96. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-1069.